Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03812744
Other study ID # 16-391 MR 1610
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2016
Est. completion date November 30, 2018

Study information

Verified date January 2019
Source Auburn University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study was designed to characterize the changes in the brain and body associated with whole coffee cherry extract (WCCE). WCCE is a patented extract of whole coffee fruit (coffee berries) from coffea arabica. Whole coffee cherries are a source of naturally occurring nutrients. There are no known side effects or allergens associated with WCCE other than that which would be associated with a consuming typical cup of coffee.

Previous studies suggest that increases in serum concentrations of both serum total and exosomal brain-derived neurotrophic factors (BDNF) may represent one of the mechanisms responsible for improved cognitive function after acute WCCE administration. Mild cognitive impairment (MCI) is an intermediate stage between the expected cognitive decline of normal aging and the more serious decline of dementia. It can involve problems with memory, language, thinking and judgment that are greater than normal age-related changes. Furthermore, MCI is associated with reduced circulating BDNF. Due to earlier studies reporting the ability of WCCE to stimulate increases in circulating and exosomal BDNF, it has been postulated that WCCE may also acutely improve cognitive function (as measured using behavioral tasks and fMRI). The purpose of this study is to extend and elucidate the findings of previous investigations by examining the acute neurophysiological effects of WCCE using blood-oxygen level dependent (BOLD) functional magnetic resonance imaging (fMRI) and magnetic resonance spectroscopy (MRS) employing a double-blind, randomized crossover design to investigate the acute effects of a single dose of WCCE or placebo (silica oxide) on neuronal activity in older participants.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date November 30, 2018
Est. primary completion date November 30, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria:

- Complaints of memory, verified by an informant

- 55 years of age or older

Exclusion Criteria:

- MRI contraindications

- Diagnosis of Alzheimer's Disease or suspected diagnosis at the time of visit by study personnel

- Significant cerebrovascular disease

- History of cardiovascular disease

- Current or recently prescribed medication known to interfere with peripheral and/or cerebral blood flow or vascular function

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Whole coffee cherry extract (WCCE)
100mg WCCE
Placebo Oral Capsule [CEBOCAP]
Silica Oxide

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Auburn University

Outcome

Type Measure Description Time frame Safety issue
Primary Behavioral Measures - Change in Go/No-Go Reaction Time Response/reaction time for each stimuli will be recorded in ms using E-Prime. Reaction times will be calculated for correct and incorrect trials separately. Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
Primary Behavioral Measures - Change in N-back Reaction Time Response/reaction time for each stimuli will be recorded in ms using E-Prime. Reaction times will be calculated for correct and incorrect trials separately. Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
Primary Behavioral Measures - Change in Go/No-Go Accuracy Accuracy will be determined as the number of trials correct, and errors will be classified as errors of omission or commission. Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
Primary Behavioral Measures - Change in N-back Accuracy Accuracy will be determined as the number of trials correct. Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
Primary Change in Concentration of Neurometabolites Magnetic resonance spectroscopy (MRS) measurements pre/post ingestion. The following are measured: glutamate, glutamine, gamma-aminobutyric acid, N-acetylaspartate, choline, creatine, glutathione, myo-inositol, aspartate, taurine, and lactate. LCModel software performed automatic quantification of in vivo proton MR spectra by analyzing spectra as a linear combination of model spectra from sequence-specific simulations. Water-suppressed spectra were eddy current corrected and quantified using the unsuppressed water signal. Cramer-Rao lower bounds were used as a measure of fit with CRLB > 50% rejected from further analysis. Metabolite concentrations were CSF-corrected, and quantified (in ppm). Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
Primary Change in Blood Levels of Brain Derived Neurotrophic Factor (BDNF) Serum and exosomal BDNF concentrations Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
Primary Blood Oxygen Level Dependent (BOLD) Changes Functional magnetic resonance imaging blood-oxygen-level-dependent signal changes across tasks, and during resting state Collected pre-drug, post-drug, pre-placebo, and post-placebo; through study completion (4 time points over a 72 hour period)
See also
  Status Clinical Trial Phase
Completed NCT01876758 - Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy N/A
Active, not recruiting NCT02255799 - Multicenter Evaluation of Memory Remediation After TBI With Donepezil Phase 3
Completed NCT03727737 - Efficacy of Repetitive Transcranial Magnetic Stimulation for Improvement of Memory in Older Adults With TBI N/A
Recruiting NCT06208943 - Neural and Cognitive Consequences of COVID-19 Survival
Completed NCT05569902 - tACS Improves Memory in Elders With Subjective Memory Complaints N/A
Completed NCT02790151 - Memory Rehabilitation by Means of Working Memory Training in Combination With a Recollection Training N/A
Active, not recruiting NCT00457769 - Aricept to Improve Functional Tasks in Vascular Dementia Phase 1
Completed NCT03872310 - Cognitive Enhancement on Working Memory in Patients With Schizophrenia N/A
Terminated NCT00531505 - Obesity and Memory, mRNA, Body Composition, Comorbidity Scale N/A
Terminated NCT02864940 - Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients N/A
Active, not recruiting NCT01123018 - Screening for Memory Studies
Completed NCT05520424 - An Exploratory Investigation of a Supplement to Promote Brain Health N/A
Completed NCT05523115 - An Exploratory Investigation of a Supplement to Promote Cognitive Health Benefits N/A
Completed NCT05051501 - The Effects of Microbiological Spectrum Changes to Improve Cognitive Health in Aging Population Phase 2
Completed NCT05170464 - The Acute Effects of Exercise and Caffeine on Working Memory During Acute Caffeine Deprivation Phase 2/Phase 3
Completed NCT02680210 - Self-defining Memories in Patients With a TBI N/A
Completed NCT02122224 - Breakfast Consumption in Preschoolers: Satiety, Diet Quality and Memory N/A
Recruiting NCT05363228 - The Effect of Tai Chi and Therapy by Dance and Movement on Blood Irisin Levels in Older Adults Over 65 Years of Age. N/A
Completed NCT01806701 - Brain Response to Treatment for Pediatric PTSD N/A